Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2764626 | 0.84 | KIF11 (0.55) | KIF11NQO2MAPTXBP1NPSR1 | |
| SCHEMBL1290586 | 0.82 | ALOX15 (0.55) | MEN1KMT2ATAS2R14KIF11KDM4E | |
| SCHEMBL31302993 | 0.78 | ALOX15 (0.43) | MEN1KMT2AMAPTKDM1AALOX15 | |
| SCHEMBL7863398 | 0.78 | PTPN5 (0.41) | MEN1KMT2ATAS2R14KIF11MAPT | |
| SCHEMBL187014 | 0.78 | NQO2 (0.61) | MEN1KMT2AKIF11KDM4ENQO2 | |
| SCHEMBL29637726 | 0.78 | PTPN5 (0.41) | MEN1KMT2ATAS2R14KIF11MAPT | |
| SCHEMBL29190680 | 0.78 | RXRA (0.47) | KIF11CES2PTPN1PTPN6 | |
| SCHEMBL815815 | 0.77 | ALDH1A1 (0.64) | MEN1KMT2AKDM4EMAPTKDM1A | |
| SCHEMBL31303011 | 0.76 | ALOX15 (0.45) | MEN1KMT2AMAPTKDM1AALOX15 | |
| SCHEMBL26062348 | 0.74 | MEN1 (0.46) | MEN1KMT2AKIF11KDM4ENQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503445-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2025-12-23 | — | — | US | disclosed |
| EP-4642772-A1 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2025-11-05 | — | — | EP | disclosed |
| EP-4642763-A1 | CRYSTALLINE FORMS OF NLRP3 INFLAMMASOME INHIBITORS, CHEMICAL PROCESSES AND CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2025-11-05 | — | — | EP | disclosed |
| US-20250326726-A1 | FERROPTOSIS INHIBITORS-PHENOXAZINE ACETAMIDES | SIRONAX BEIJING CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-4628490-A2 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4363406-B1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2025-09-10 | — | — | EP | disclosed |
| CN-113508168-B | Compound, liquid crystal medium and liquid crystal display comprising same | 默克专利股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-4543863-A1 | FERROPTOSIS INHIBITORS AND USES THEREOF | University Of Ottawa (CA) | 2025-04-30 | — | — | EP | disclosed |
| CN-119866332-A | Iron death inhibitor-phenoxazine acetamides | 维泰瑞隆（北京）生物科技有限公司 | 2025-04-22 | — | — | CN | disclosed |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| EP-1204658-B1 | BENZOFURYLPIPERAZINE SEROTONIN AGONISTS | LILLY CO ELI (US) | 2003-05-07 | — | — | EP | disclosed |
| CN-1407982-A | Serotonergic benzofurans | LILLY CO ELI (US) | 2003-04-02 | — | — | CN | disclosed |
| WO-2003010158-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
| CN-1365359-A | Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists | LILLY CO ELI (US) | 2002-08-21 | — | — | CN | disclosed |
| EP-1204658-A1 | BENZOFURYLPIPERAZINE SEROTONIN AGONISTS | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1204659-A2 | SEROTONERGIC BENZOFURANS | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1204654-A1 | BENZOFURYLPIPERAZINES AND BENZOFURYLHOMOPIPERAZINES: SEROTONIN AGONISTS | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2001009123-A1 | BENZOFURYLPIPERAZINE SEROTONIN AGONISTS | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001009122-A2 | SEROTONERGIC BENZOFURANS | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2001009111-A1 | BENZOFURYLPIPERAZINES AND BENZOFURYLHOMOPIPERAZINES: SEROTONIN AGONISTS | ELI LILLY AND COMPANY (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326726-A1 | FERROPTOSIS INHIBITORS-PHENOXAZINE ACETAMIDES | AIFM2, GPX4, FECH | MEN1 2988/4885KMT2A 2563/4885TAS2R14 1068/4885 |
| US-12503445-B2 | Compounds and their use | NLRP3, PYCARD, NLRP1 | MEN1 3261/4885KMT2A 2976/4885TAS2R14 3202/4885 |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | CCR1, SSB, C5 | MEN1 2779/4885KMT2A 2306/4885TAS2R14 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.